In the present investigation, the cardiotoxic effects of three anthracycline analogs (doxorubicin, 4′-epi-doxorubicin and 4′-deoxy-doxorubicin) were compared. For this purpose, 9.0 mg/kg of doxorubicin, divided into three closely spaced sub-doses, were injected intravenously in rats. The two derivatives were administered according to the same time schedule and their doses were chosen on the basis of the clinically adopted ratio, doxorubicin : 4′-epidoxorubicin : 4′-deoxy-doxorubicin = 1:1: 0.5. The degree of cardiomyopathy induced by the three anthracyclines was evaluated by ECG changes and morphological alterations. Doxorubicin was found to produce a significant degree of cardiotoxicity, thus confirming the validity of the experimental model adopted. Both 4′-substituted derivatives proved to be less cardiotoxic than the parent compound, although not completely devoid of this side effect.
Get full access to this article
View all access options for this article.
References
1.
BachurN.R., GordonS.L., GeeM.V.: Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.Mol. Pharmacol.,13: 901–910, 1977.
2.
BalcuevaE., SchoibergC., MasudK., DimitrovN.: Determination of early adriamycin induced cardiotoxicity by impedance cardiography. In « Current Chemotherapy », SiegenthalerR., LuthyR. eds., pp. 1253–1255, Am. Soc. Microbiol., Washington D.C., 1978.
3.
BertazzoliC., SammartiniU., BalconiF., RoverC., NasiniA.N., Dell'OroI., AntongiovanniV., TosanaM.G., LuxB.: Experimental toxicology of 4′-deoxydoxorubicin. Proceedings of the 13th International Cancer Congress, Seattle, n. 2325, p. 407, 1982.
4.
BonfanteV., FerrariL., BrambillaC., RossiA., VillaniF., CrippaF., ValagussaP., BonadonnaG.: New anthracycline analogs in advanced breast cancer.Eur. J. Cancer Clin. Oncol.,22: 1379–1385, 1986.
5.
BrambillaC., RossiA., BonfanteV., FerrariL., VillaniF., CrippaF., BonadonnaG.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer.Cancer Treat. Rep.,70: 261–266, 1986.
6.
CarlssonR.W., WilliamsR.D., BillinghamM.E., PavlosC.L., HanniganJ.F., KohlerM., TortiF.: Assessment of the cardiac toxicity of 4′-deoxydoxorubicin (DxDx) utilizing the endomyocardial biopsy: the NGOG experience.Am. Assoc., Cancer Oncol.,5: 52, 1986.
7.
CasazzaA.M., Di MarcoA., BonadonnaG., BonfanteV., BertazzoliC., BelliniO., PratesiG., SalaL., BalleriniC.: Effect of modifications in position 4 of the chromophore or in position 4’ of the aminosugar on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: « Anthra-cyclines: current status and new developments»,CrookeS.T., ReichS.D. eds., pp. 403–430, Academic Press, New York, 1980.
8.
CersosimoR.J., Ki HongW.: Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.J. Clin. Oncol.,4: 425–439, 1986.
9.
DickinsonA.C., De YordyJ.D., BoutinM.G., TeresD.: Absence of generation of oxygen-containing free radicals with 4′-deoxy-doxorubicin.Biochem. Biophys. Res. Commun.,125: 584–591, 1984.
FormelliF., CasazzaA.M.: Relationship between tissue distribution and toxicity of new anthracyclines in mice. In: «Current chemotherapy and immunotherapy», PeritiP., Gialdroni GrassiG. eds., pp. 1451–1453, Am. Soc. Microbiol., Washington D.C.,2: 1981.
12.
FormelliF., PolliniC., CasazzaA.M., Di MarcoA., MarconiA.: Fluorescence assay and pharmacokinetic studies of 4′-deoxy-doxorubicin and doxorubicin in organs of mice bearing solid tumors.Cancer Chemother. Pharmacol.,5: 139–144, 1981.
13.
HandaK., SatoS.: Generation of free radicals of quinone group-containing anticancer chemicals in NADPH-micro-some system as evidenced by initiation of sulfite oxidation.Gann.,66: 43–47, 1979.
14.
IwamotoY., HausenI.L., PorterT.H.: Inhibition of coenzyme QlO-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity.Biochem. Biophys. Res. Commun.,58: 633–638, 1974.
15.
JainK.K., CaspersE.S., GellerN.L., HakesT.B., KaufmanR.J., CurrieV., SchwartzW., CassidyC., PetroniG.R., YoungC.W., WittesR.E.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.J. Clin. Oncol.,3: 818–826, 1985.
16.
LesuyS.F., MileiJ., MolinaH., BoverisA., MileiS.: Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4′-epi-adriamycin in mice.Tumori,71: 241–249, 1985.
17.
MontiE., PiccininiF., VillaniF., FavalliL.: Myocardial contractility and heart pharmacokinetics of doxorubicin after a single i.v. administration in rat.Cancer Chemother. Pharmacol,18: 289–291, 1986.
18.
NataleN., BrambillaM., LuchiniS., MartiniA., MoroE., PacciariniM.A., TamassiaV., VagoG., TrabottoniA.: 4′-epi-doxorubicin and doxorubicin: toxicity and pharmacokinetics of cancer patients. In: Current Chemotherapy and Im-munotherapy.PeritiP., Gialdroni GrassiG. (eds.), pp. 1447–1449, Am. Soc. Microbiol, Washington D.C., 1981.
19.
RausaL., D'AlessandroN., DusonchetL., CrescimannoM., CrostaL., FlandinaC., PalmeriS., SanguedolceR.: Pharmacodynamic effect on heart of mice treated with doxorubicin and 4′-deoxy-doxorubicin.Proceedings of the 13th International Cancer Congress, Seattle, n. 2324, p. 407, 1982.
20.
SolciaE., BalleriniL., BelliniO., MagriniU., BertazzoliC., TosanaG., SalaL., BalconiF., RalloR.: Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions.Tumori,67: 461–472, 1981.
21.
VillaniF., BerettaG., GuindaniA.: Evaluation of early doxorubicin induced cardiotoxicity by means of systolic time intervals.Cancer Chemother. Pharmacol.,3: 249–251, 1979.
22.
VillaniF., MontiE., PiccininiF., FavalliL., LanzaE., Rozza DionigiA., PoggiP.: Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats.Tumori,72: 323–329, 1986.
23.
VillaniF., GalimbertiM., ComazziR., CrippaF., BonfanteV., FerrariL., PacciariniM.A.: Clinical evaluation of the cardiac toxicity of 4′-deoxy-doxorubicin.Int. J. Clin. Pharmacol. Ther. Toxicol.,36: 185–189, 1988.
24.
Von HoffD.D., RozencweigM., PiccartM.: The cardiotoxicity of anticancer agents.Semin. Oncol.,9: 23–33, 1982.
25.
WeenenH., LankelmaJ.P., PendersP.G.M., McVieJ.G., Ten Bokkel HuininkW.W., De PlanqueM.M., PinedoH.M.: Pharmacokinetics of 4′-epi-doxorubicin in man.Invest. New Drugs,1: 59–64, 1983.
26.
WeissR.B., SarosyG., Clagett-CarrK., RussoM., Leyland-JonesB.: Anthracycline analogs: the past, present and future.Cancer Chemother. Pharmacol,18: 185–197, 1986.
27.
YoungC.W.: Epirubicin: a therapeutically active doxorubicin analogue with reduced cardiotoxicity. In: Advances in Anthracycline Chemotherapy: Epirubicin.BonadonnaG. (ed.), pp. 183–188, Masson Italia Editori, Milano, 1984.
28.
YoungR.C., OzolsR.F., MyersC.E.: The anthracycline antineoplastic drugs.N. Engl. J. Med.,305: 139–153, 1981.
